CLOVER CORPORATION LIMITED (CLV)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:

CLV - CLOVER CORPORATION LIMITED
FNArena Sector : Health & Nutrition
Year End: July
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.08
Index: ALL-ORDS
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.83
30 Nov |
OPEN $0.86 |
HIGH $0.86 |
34,133 LOW $0.83 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 100% |
OTHER COMPANIES IN THE SAME SECTOR | |||
EBO . EXL . MCP . SIG . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
---|---|---|---|---|
EPS (cps) | xxx | 3.7 | 5.0 | xxx |
DPS (cps) | xxx | 1.5 | N/A | xxx |
EPS Growth | xxx | - 13.3% | 34.4% | xxx |
DPS Growth | xxx | 0.0% | N/A | xxx |
PE Ratio | xxx | N/A | 17.2 | xxx |
Dividend Yield | xxx | N/A | 0.0% | xxx |
Div Pay Ratio(%) | xxx | 40.3% | 0.0% | xxx |
Last ex-div: 30/10 - ex-div 0.75c (franking 100%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | 3.7 |
DPS All | xxx | xxx | xxx | xxx | xxx | 1.5 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 79.9 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 40.2 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 6.7 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 7.77 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 9.53 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 8.27 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | 7.02 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | 9.53 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 12.94 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 2.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 2 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 10 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 12 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 2 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 9 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 2.71 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 1.6 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 2.05 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 56 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 14 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 3 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 12 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
CLV STOCK CHART

FNArena News on CLV
1 |
Australian Broker Call *Extra* Edition – Nov 29, 2023Nov 29 2023 - Daily Market Reports |
2 |
FNArena Corporate Results Monitor – 29-09-2023Sep 29 2023 - Australia |
3 |
Weekly Ratings, Targets, Forecast Changes – 17-03-23Mar 20 2023 - Weekly Reports |
4 |
FNArena Corporate Results Monitor – 17-03-2023Mar 17 2023 - Australia |
5 |
FNArena Corporate Results Monitor – 26-09-2022Sep 26 2022 - Australia |
Latest Health & Nutrition News
1 |
Sigma Healthcare Promises Higher MarginsOct 03 2023 - Small Caps |
2 |
Sigma’s Win Not Neccessarily Ebos’ LossJun 14 2023 - Small Caps |
3 |
Sigma Healthcare: Brokers WaryMar 31 2022 - Australia |
4 |
Health & Wellness Boom On The ASXApr 29 2021 - Weekly Reports |
5 |
M&A Now On Sigma Healthcare’s AgendaMar 24 2021 - Australia |
6 |
McPherson’s Expands Into Herbal HealthNov 04 2020 - Small Caps |
7 |
Nine Ignored Companies Now Worth A LookSep 23 2020 - FYI |
8 |
Next Week At A Glance – 14-18 Sep 2020Sep 11 2020 - Weekly Reports |
9 |
Sigma Farewells API, Heralds New ContractDec 17 2019 - Australia |
10 |
Blackmores: Hopes Pinned On RestructuringNov 01 2019 - Australia |